Newsroom

Sight Sciences Announces Pricing of Initial Public Offering

Sight Sciences Announces Pricing of Initial Public Offering

read more +
Sight Sciences Announces Substantial Crossover Raise

Funds will be used to continue clinical and commercial acceleration

read more +
Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors

Highly accomplished industry executive brings financial and operational expertise to innovative eye care company

read more +
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

Industry veterans will lead scaling of company operations and processes to support OMNI Surgical System and TearCare growth

read more +
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D.

read more +
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and […]

read more +
Event: American Academy of Ophthalmology (AAOph)

Event Details November 13-16 New Orleans, LA Contact Sight Sciences today to schedule a meeting.

read more +
Event: OSN NY

Event Details October 15-17 New York, NY Contact Sight Sciences today to schedule a meeting.

read more +